HCV protease field hots up as Vertex completes US NDA submission for telaprevir
This article was originally published in Scrip
Executive Summary
Vertex Pharmaceuticals has completed its rolling NDA submission for US regulators on its investigational protease inhibitor, telaprevir, as a treatment for people with hepatitis C, and it now seeks an expedited review – in part based on results showing that the new drug could cut the current standard treatment time in half for a large number of patients.